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Background:Although repair of large abdominal aortic aneurysms (AAAs) is well accepted, randomized clinical trials have
failed to demonstrate benefit for early surgical repair of small aneurysms compared with surveillance. Endovascular repair
has been shown to be safer than open surgical repair in patients with large aneurysms, prompting a randomized trial of
early endovascular repair vs surveillance in patients with small aneurysms.
Methods: We randomly assigned 728 patients (13.3% women; mean age, 71  8 years) with 4 to 5 cm AAAs to early
endovascular repair (366 patients) or ultrasound surveillance (362 patients). Rupture or aneurysm-related death and
overall mortality in the two groups were compared during a mean follow-up of 20  12 months.
Results: Among patients randomized to treatment, 89% underwent aneurysm repair. Among patients randomized to
surveillance, 31% underwent aneurysm repair during the course of the study. After a mean follow-up of 20 12 months
(range, 0-41 months), 15 deaths had occurred in each group (4.1%). The unadjusted hazard ratio (95% confidence
interval) for mortality after early endovascular repair was 1.01 (0.49-2.07, P  .98). Aneurysm rupture or aneurysm-
related death occurred in two patients in each group (0.6%). The unadjusted hazard ratio was 0.99 (0.14-7.06, P  .99)
for early endovascular repair.
Conclusions: Early treatment with endovascular repair and rigorous surveillance with selective aneurysm treatment as
indicated both appear to be safe alternatives for patients with small AAAs, protecting the patient from rupture or
aneurysm-related death for at least 3 years. ( J Vasc Surg 2010;51:1081-7.)Aortic aneurysm repair is performed to prevent rupture,
an event strongly correlated with the diameter of the aneu-
rysm.1 The mortality from aneurysm repair itself, however,
can be significant.2 Operative risk must be balanced against
the risk of rupture when deciding between repair and
observation. Repair is indicated in most patients with larger
aneurysms, but two prospective randomized clinical trials
failed to detect benefits of early open surgical repair com-
pared with surveillance in patients with small aneurysms
of 5.5 cm in diameter.3,4
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doi:10.1016/j.jvs.2009.10.113Operative mortality rates of 2.7% and 5.8% in these two
trials raised the question of whether a procedure with lower
operative mortality might provide benefit compared with ob-
servation in patientswith smaller aneurysms, and endovascular
aneurysm repair (EVAR) has been shown to have a lower
perioperative mortality rate than open surgical repair.5-7 The
Positive Impact of Endovascular Options for Treating Aneu-
rysms Early (PIVOTAL) trial was organized to determine
whether early EVAR reduced the risk of rupture or aneurysm-
related death compared with surveillance in patients with
small (4- to 5-cm) abdominal aortic aneurysms (AAAs). Here
we report the early results of this first randomized clinical trial
comparing the two modalities.
METHODS
Study design. The trial was approved by the human
subject research committees of each participating center. The
trial management was coordinated centrally by a steering
committee, and the safety of the study was monitored by an
independent patient safety committee that met biannually.
Eligible patients were aged between 40 and 90 years,
with infrarenal AAAs between 4.0 and 5.0 cm in diameter
by computed tomography (CT) performed 3 months of
screening. Patients were excluded from the study if they
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abdominal or thoracic aortic repair, an aneurysm originat-
ing 1.0 cm from the most distal main renal artery, life
expectancy of 3 years, inability to provide informed con-
sent, predicted noncompliance with the protocol, Society
for Vascular Surgery (SVS) score2, with the exception of
age and controlled hypertension, baseline serum creatinine
level 2.5 mg/dL, or when the patient did not meet the
indications for use for the endograft device. The Cleveland
Clinic coordinating center managed the study and was
responsible for randomization, study patient monitoring,
data acquisition, and data analysis. The study is registered
on clinicaltrials.gov (NCT00444821).
Randomization, treatment, and follow-up. The
randomization procedure was created with equal probabil-
ity of assignment to each of the treatment groups by means
of a computer-generated random-number code that was
maintained at the coordinating center. Patients assigned to
early EVAR underwent aneurysm repair 30 days of ran-
domization using any approvedMedtronic endograft system
(Medtronic, Santa Rosa, Calif). Before April 16, 2008, the
implanted devices were the commercially available AneuRx
device. After approval of the Talent device on April 2008,
investigators could choose between the two. Follow-up
analyses were scheduled for 1 month, 6 months, and every
6 months thereafter for a minimum of 36 months to a
maximum of 60 months after operation. Imaging studies
were scheduled for the 1-month, 6-month, and yearly visits
and included CT scan with contrast, magnetic resonance
scan, or a CT without contrast plus a duplex ultrasound
study.
Individuals in the surveillance group were scheduled to
undergo assessments every 6 months for a minimum of 36
months up to 60 months after randomization. An ultrasound
orCT scanwas performed at each assessment to assess the size
of the aneurysm. Patients were offered aneurysm repair when
symptoms thought referable to the aneurysm developed,
when the diameter of the aneurysm reached 5.5 cm, or when
the aneurysm enlarged 0.5 cm between any two 6-month
assessments.When one of these criteria wasmet, endovascular
or open surgical repair was advised.
Outcomemeasures. The primary objective of the trial
was to determine whether early endovascular repair of
aneurysms 4.0 to 5.0 cm in diameter is superior to surveil-
lance with respect to the frequency of rupture or aneurysm-
related death. The primary end point was the composite
end point of rupture or aneurysm-related death, assessed
through 3 years after randomization. Death was considered
to be aneurysm-related when it occurred as a result of
rupture or when it occurred 30 days of any operative
procedure for aneurysm repair, whether the procedure was
the primary endovascular or open repair, or a secondary
procedure for remediation of problems from the first repair.
Statistical analysis. The sample size was based on the
primary outcome of time to rupture or aneurysm-related
death. The event rate for the composite outcome was esti-
mated to be 1.7% per year in the surveillance group and 0.7%
in the EVAR group corresponding to a hazard ratio of 0.42(0.71/1.70) for surveillance vs early EVAR.3,8,9 Sample size
calculations assumed that the primary outcome would be
evaluated 3 years after enrollment of the last patient, a 2.5-year
accrual time, and an 18% loss to follow-up that would follow
an exponential distribution. These estimates suggested that
1050 total patients, or 525 per group, would be necessary to
detect a hazard ratio of 0.42 with 80% power at a signifi-
cance level of 0.05. The estimates also assumed a constant
hazard over time, but the actual analyses would account for
nonconstant hazard in either or both groups.
Analyses of the primary end point and overall mortality
were performed on an intent-to-treat basis using the log-
rank test. Differences in the risk of end points between
treatment groups were described using hazard ratios from
Cox models. Kaplan-Meier analysis was used to estimate
rates of other events during follow-up. Categoric factors
were compared between treatment groups using 2 or
Fisher’s exact tests, and continuous measures were com-
pared using t tests. Analyses were performed using Stat-
View 9.1 software (SAS Institute, Cary, NC), and all com-
parisons assumed a .05 significance level.
RESULTS
Study group. Among 4665 patients screened, 728
(15.6%) were randomized (Fig 1). Of the 631men (86.7%)
and 97 women (13.3%), 366 were assigned to early endo-
vascular repair and 362 to ultrasound surveillance. The
mean initial diameter was 4.5  0.3 cm in both groups.
Mean ages were 70.5  7.8 years for patients assigned to
the early EVAR and 70.5  7.7 years for those assigned to
surveillance. Other baseline characteristics are listed in Ta-
ble I. The only significant difference between the two
treatment arms was a higher rate of neurologic disease in
the early repair group (P  .03). The mean follow-up was
20  12 months (range, 0-41 months) in each treatment
group.
Aneurysm repair. Patients assigned to the early EVAR
treatment arm underwent aneurysm repair a mean of 29.5
days (95% confidence interval [CI], 25-34 days) days after
Fig 1. Flow chart shows patients, randomization, and out-
comes.
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group who underwent an attempt at endovascular repair
with a protocol device and within the specified time win-
dow, 321 (99.7%) had successful delivery and deployment.
Among the 40 patients who did not receive the specified
therapy, 6 underwent repair outside of the 30-day window
after randomization, 9 were withdrawn at the patient’s
request, 10 were withdrawn by the treating physician for
deteriorating health status between randomization and
scheduled repair, and 2 were treated with an endograft
device that was not in the protocol. The reasons for nonre-
pair in the remaining 13 patients were unspecified. Data
outlining the outcome measures in the two groups are
listed in Table II.
Endovascular procedures averaged 125 minutes in du-
ration (95% CI, 118-132 minutes). The estimated blood
loss of the procedures was 254 mL (95% CI, 225-283 mL).
The length of hospital stay averaged 1.6 days (95% CI,




Male gender, n/N (%) 306
White race, n/N (%) 343
Baseline AAA size, mean (SD) cm
Hispanic ethnicity, n/N (%) 7
Creatinine, mean (SD) mg/dL
Tobacco use, n/N 316







Medical history, n/N (%)
Family history of aneurysmal disease 77
Cardiovascular history
Myocardial infarction 106
Congestive heart failure 22
Coronary artery disease 195
Cardiac arrhythmia 70
Thrombolysis 22












AAA, Abdominal aortic aneurysm; ACE, angiotensin-converting enzyme in
deviation.
aDerived from Pearson 2 test unless otherwise specified.
bDerived from two-sample t tests assuming unequal variances.
cFisher’s exact test.1.5-1.7 days). Graft limb thrombosis occurred in 18 pa-tients through one year, with similar frequency in the
early-EVAR group (13 patients, 4.8%) and the surveillance
group (5 patients, 5.8%). An endoleak was documented in
36 patients (11.9%) at 30 days and in 72 (26%) at some
time1 year after the initial procedure. After repair, aneu-
rysm enlargement by 0.5 cm was observed in 15 patients
(5.7%) at 1 year of follow-up.
In the surveillance arm, 112 patients (30.9%) under-
went aneurysm repair (Fig 2). The average time from
randomization to repair was 370 days, and the average size
of the aneurysms at the last imaging report before repair
was 4.9 cm (range, 4.0-6.5 cm). Among these, 109 (97.3%)
underwent EVAR and 3 (2.7%) had an open surgical repair.
The most frequent reasons for aneurysm repair in the
surveillance group were growth of the aneurysm in 77
(70.6%), patient anxiety and request for repair in 12
(11.0%), and the development of aneurysm-related symp-
toms in 8 (7.4%). The rate of aneurysm repair in the
lance Early repair Pa
(7.67) 70.46 (7.80) .99
(84.5) 325/366 (88.8) .09
(94.8) 340/366 (92.9) .3
(0.27) 4.45 (0.27) .8
(1.9) 7/366 (1.9) .98
(0.27) 1.14 (0.29) .10b
(91.9) 317/352 (90.1) .41
(80.1) 281/349 (80.5) .89
(93.2) 267/281 (95.0) .35
(11.5) 29/281 (10.3) .65
(43.2) 136/351 (38.7) .23
(51.0) 184/350 (52.6) .68
(78.4) 267/351 (76.1) .47
(26.1) 62/298 (20.8) .13
(31.5) 107/344 (31.1) .92
(6.5) 21/353 (5.9) .77
(56.5) 190/350 (54.3) .55
(21.1) 59/341 (17.3) .21
(6.7) 12/333 (3.6) .07
(27.6) 99/344 (28.8) .74
(76.5) 279/353 (79.0) .42
(39.8) 135/351 (38.5) .71
(23.5) 73/344 (21.2) .47
(0.0) 0/355 (0.0) NA
(21.7) 70/354 (19.8) .54
(0.9) 2/341 (0.6) .68c
(39.8) 133/353 (37.7) .57
(2.3) 10/352 (2.8) .68
(24.4) 91/352 (25.9) .66
(11.7) 62/355 (17.5) .03































hibitosurveillance group increased with increasing baseline diam-
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of repair was 19.6% among patients with aneurysm diame-
ters of 4.00 to 4.25 cm compared with 56.4% in patients
with aneurysms with diameters of 4.75 to 5.00 cm.
Mortality. The 30-day operative mortality rate in the
early EVAR group was 0.6% (2 of 322). There were no
deaths 30 days of randomization in the surveillance
group. Among 109 surveilled patients who eventually un-
derwent aneurysm repair, the 30-day operative mortality
was 0.9% (1 of 109). After a mean follow-up of 20  12
months (range, 0-41months), there were 15 deaths in each
group (4.1%), and the unadjusted hazard ratio for mortality
in the early-EVAR group was 1.01 (95% CI, 0.49-2.07,
P  .98; Fig 3).
Rupture or aneurysm-related death. Aneurysm rup-
ture or aneurysm-related death occurred in two patients
(0.6%) in the early EVAR group and in two patients (0.6%)
in the surveillance group. One patient in the early-EVAR
group died of multisystem organ failure during the hospi-
talization for aneurysm repair, and the second died of a
fall-related intracranial hemorrhage 30 days after a sec-
ondary procedure to treat an endoleak. One patient in the
Table II. Frequency of the major end points in







Randomized patients 362/728 (49.7) 366/728 (50.3)
Received endograft device 109/362 (30.1) 322/366 (88.9)
Open surgery 3/362 (0.8) 5/366 (1.4)
Received repair 112/362 (30.9) 326/366 (89.1)
Successful delivery 109/109 (100) 321/322 (99.7)
Successful deployment 109/109 (100) 321/322 (99.7)
Rate of endograft implant
4.00-4.25 19/102(18.6) 86/96 (89.6)
4.26-4.50 36/116 (31.0) 109/120 (90.8)
4.51-4.75 24/73 (32.9) 65/69 (94.2)
4.76-5.00 30/55 (54.6) 51/59 (86.4)
Rate of repair (open and
endograft)
4.00-4.25 20/102 (19.6) 87/96 (90.6)
4.26-4.50 37/116 (31.9) 110/120 (91.7)
4.51-4.75 24/73 (32.9) 65/69 (94.2)
4.76-5.00 31/55 (56.4) 53/59 (89.8)
30-day overall mortality
From randomization 0/362 (0.0) 1/366 (0.3)
From repair 1/109 (0.9) 1/322 (0.3)
Overall mortality 15/362 (4.1) 15/366 (4.1)
Composite end point 2/362 (0.6) 2/366 (0.5)
Aneurysm rupture 1/362 (0.3) 0/366 (0.0)
Aneurysm-related mortality 1/362 (0.3) 2/366 (0.5)
Secondary interventions 5/109 (4.6) 12/322 (3.7)
Secondary interventions, No.
1 4/109 (3.7) 11/322 (3.4)
2 1/109 (0.9) 1/322 (0.3)
Surgery 30-day
randomization window 13/351 (3.7) 254/353 (72.0)
EVAR, Endovascular aneurysm repair.
aThe data are number of patients (percent).surveillance group experienced aneurysm rupture and sur-vived emergency EVAR. A second patient in this group
underwent EVAR and died 30 days of the procedure.
The primary end point—time to rupture or aneurysm-
related death—was similar in the two treatment groups (Fig
4). The unadjusted hazard ratio was 0.99 (95% CI, 0.14-
7.06, P  .99) in the early EVAR group. There was no
evidence of nonproportional hazards between the two
groups over time; survival was similar in the two groups
early as well as later after randomization.
Other perioperative complications and secondary
procedures. Major perioperative complications in the pa-
tients who underwent aneurysm repair in the early EVAR
group (322 patients) and the surveillance group (112 pa-
tients) are listed in Table III. The most frequent complica-
tions were vascular, usually at the femoral entry site, fol-
lowed by wound infections, cardiac events, and pulmonary
complications. Endograft migration occurred in two pa-
tients through 1 year of follow-up; one was in a patient in
the early EVAR group (0.3%) and the other was in a patient
initially randomized to surveillance (1.3%). Graft limb
thrombosis occurred in 18 patients through 1 year at a
similar frequency between groups, consisting of 13 pa-
tients (4.8%) in the early EVAR group and 5 (5.8%) in
the surveillance group. Endoleaks were noted in just
10% of patients and were most often of the type II
variety (Table IV).
There were 19 secondary procedures, including 8 pro-
cedures for graft limb occlusion, 9 for endoleak (2 for type
I and 7 for type II leaks), and 2 for graft kinks or limb
stenoses. There were 20 readmissions: 18 for secondary
endovascular procedures and 2 for conversion to open
repair after attempted endovascular graft implantation.
Two patients in the early EVAR group required open
surgical graft repair, one at 48 days after the endograft
implantation due to iliac occlusion and one at 60 days after
an unsuccessful attempted EVAR implant.
DISCUSSION
The prevalence of AAAs, a preventable cause of death,
is increasing. Rupture of an aneurysm is unpredictable,
rarely foreshowed by warning symptoms but lethal in up to
90%.10 Recognition of these facts led to United States
Congressional approval in 2007 of the SAAVE act to
support ultrasound screening for aneurysms.11 The risk of
aneurysm rupture is related to aneurysm size, with large aneu-
rysmsmore likely to rupture than small aneurysms. Treatment
decisions for an individual patient are based on weighing the
estimated risk of rupture against the estimated risk of death
from treatment. Although the balance is clearly in favor of
treating large aneurysms, there remains uncertainty for treat-
ing smaller aneurysms, and several prospective randomized
trials have been conducted to address this question.
In this study, we sought to clarify the distinction
between small and large aneurysms by defining small
aneurysms as those 5.0 cm in diameter. Aneurysms of
this size can rupture: the United Kingdom Small Aneu-
rysm Trial (UKSAT) reported a rupture rate of approxi-
mately 1% per year.1 When an AAA is detected, the
).
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or observation is indicated, a decision that is based on the
relative risk of aneurysm rupture compared with the risk
of repair.
Two randomized trials of patients with small aneurysms
failed to detect benefit with early open surgical repair
Fig 2. Cumulative rate of repair of abdominal aortic an
or early endovascular aneurysm repair (EVAR, solid line
Fig 3. Kaplan-Meier estimates show the composite e
according to assignment to surveillance (dashed line) or
time to the composite end point did not significantly difcompared with surveillance:● The UKSAT randomly assigned 1090 patients with
4.0- to 5.5-cm aneurysms to early open surgical repair
or ultrasound surveillance. Survival after 8 years of
follow-up was 7% greater in the early surgery group, a
finding limited to that specific time point and one that
was attributed to a higher rate of smoking cessation in
m according to assignment to surveillance (dashed line)
oint of aneurysm-related death or aneurysm rupture
endovascular aneurysm repair (EVAR, solid line). The
tween groups (P  .99).eurysnd p
earlythe surgical group.8
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Veterans Affairs Cooperative Study assigned 569 pa-
tients with 4.0- to 5.4-cm aneurysms to open repair or
surveillance, and the observations were similar to those
Fig 4. Kaplan-Meier estimates of overall survival with
surveillance (dashed line) or early endovascular aneurysm
differ between groups (P  .98).
Table III. Adverse events (30 days) in the early
endovascular repair group and the surveillance group
among patients who underwent aneurysm repair








Endoleak 27 8 35
Endograft limb thrombosis 4 3 7
Endograft migration 1 0 1
Vascular complications 10 3 13
Deep venous thrombosis 1 0 1
Superficial wound infection 8 1 9
Other serious wound infections 3 1 4
Distal embolization to LE 1 1 2
Prolonged ileus (4 d) 4 0 4
Prolonged fever (4 d) 3 0 3
Q-wave myocardial infarction 1 1 2
Other serious cardiac events 6 5 11
Mesenteric ischemia 1 0 1
Multisystem organ failure 1 0 1
Prolonged intubation (24 h) 1 0 1
Other serious pulmonary events 3 1 4
Transient creatinine increase 2 0 2
Persistent creatinine increase 0 1 1
Temporary hemodialysis 1 0 1
Other serious renal events 3 0 3
EVAR, Endovascular aneurysm repair; LE, lower extremities.of the United Kingdom group.Overall survival as an end point, however, maymask the
beneficial effects of aneurysm treatment in prevention of
rupture or aneurysm-related death. Most of the patients in
both the UKSAT and ADAM studies died of non-AAA or
treatment-related causes, and patients in both groups died
at about the same rates.
The two studies of open surgical repair vs surveillance
have been criticized with respect to the high operative
onfidence limits are shown according to assignment to
r (EVAR, solid line). Overall survival did not significantly







Stent migration, 1 y 1 (1.3) 1 (0.3)
Thrombosis, 1y 5 (5.8) 13 (4.8)
All endoleaks
30 d 10 (10.3) 36 (11.9)
1 y 30 (35.1) 72 (26.1)
Type I endoleaks
30 d 1 (1.0) 0 (0.0)
1 y 2 (2.4) 2 (0.7)
Type II endoleaks
30 d 9 (9.3) 34 (11.3)
1 y 29 (33.4) 67 (24.4)
Type III endoleaks
30 d 0 (0.0) 1 (0.3)
1 y 0 (0.0) 1 (0.3)
Type IV endoleaks
30 d 0 (0.0) 1 (0.3)
1 y 0 (0.0) 2 (0.7)
Aneurysm enlargement, 1 y 35 (14.2) 15 (5.7)
Est, Estimated; EVAR, endovascular aneurysm repair.95% c
repaimortality rates.12 The United Kingdom trial, for instance,
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surgical group.4 Noting data that suggest a lower operative
mortality rate with EVAR,5 we tested the hypothesis that
the survival cross-over and payback of EVAR might occur
earlier and differences might be more robust than what was
observed after open surgical repair.
The early results of the present study confirm the safety
of EVAR in patients with small 4- to 5-cm aneurysms. The
rate of perioperative mortality was only 0.6%, and the
3-year rate of rupture or aneurysm-related mortality was
near zero. This observation suggests that early EVAR
would be of benefit in preventing rupture, provided the rate
of aneurysm rupture is sufficiently high in the surveillance
group. Unexpectedly, however, the observed risk of rup-
ture in the surveillance group was significantly lower than
predicted. Unless the risk of rupture increases in a nonlinear
fashion over time, the chance of demonstrating differences
in the primary outcome measure of rupture or aneurysm-
related death was 1% in a futility analysis. This interim
analysis was performed to determine whether continued
enrollment would be likely to demonstrate benefit of one
group over the other. In fact, the rate of aneurysm rupture
would have to increase about eightfold in the surveillance
group for any statistically significant difference to be ob-
served at the end of the study. This futility analysis triggered
the trialists’ decision to close the trial to patient enrollment
before its planned enrollment of 1050 patients but to
continue with the planned follow-up of existing patients.
The reasons for the lower-than-expected rate of rup-
ture in this study are unclear. Compared with prior
series, the present study enrolled patients with smaller
aneurysms who were more frequently treated with statins
and -blockers, medications that may prevent aneurysm
enlargement or rupture.13,14 Further, the present study
mandated rigorous surveillance that resulted in aneurysm
repair for 30% of the surveillance group 3 years after
randomization, potentially lowering the rupture rate in this
group. These results are strikingly similar to those in the
surveillance arm of the UKSAT, in which small aneurysms
were repaired in a significant proportion of patients after a
relatively short period of observation.4
CONCLUSIONS
Until longer follow-up data from this study are avail-
able, early treatment with EVAR and image-based surveil-
lance, and aneurysm treatment as clinically indicated, both
appear to be safe alternatives for patients with small aneu-
rysms of 4.0 to 5.0 cm in diameter. One must caution,
however, that this recommendation is based on early data
that might change as longer-term data accrues. Further, the
finding must be taken in the context of the very low
operative mortality rate after EVAR performed by the
experienced trial surgeons and the diligence of the
follow-up in the surveilled patients. Patients who are non-
compliant with imaging protocols comprise a particularly
challenging subgroup for whom neither surveillance withselected repair, endovascular repair, nor even open surgery
provide a safe option. Efforts in this subgroup should be
directed at education and active tactics to encourage
follow-up imaging studies. For now, decisions should
be individualized and based on the size of the aneurysm,
the medical condition of the patient, the likelihood of the
patient following a rigorous surveillance protocol, and the
surgeon’s expertise in EVAR.
AUTHOR CONTRIBUTIONS
Conception and design: KO, DG, KK, CZ
Analysis and interpretation: KO, DG, KK, CZ
Data collection: The Cleveland Clinic CRO
Writing the article: KO, CZ
Critical revision of the article: DC, KK
Final approval of the article: KO, DC, KK, CZ
Statistical analysis: KO
Obtained funding: KO, DC
Overall responsibility: KO
REFERENCES
1. Powell JT, Brown LC. The natural history of abdominal aortic aneu-
rysms and their risk of rupture. Acta Chir Belg 2001;101:11-6.
2. Filipovic M, Goldacre MJ, Gill L. Elective surgery for aortic abdominal
aneurysm: comparison of English outcomes with those elsewhere. J
Epidemiol Community Health 2007;61:226-31.
3. Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, Acher
CW, et al. Immediate repair compared with surveillance of small ab-
dominal aortic aneurysms. N Engl J Med 2002;346:1437-44.
4. Powell JT, Brown LC, Forbes JF, Fowkes FG, Greenhalgh RM, Ruckley
CV, et al. Final 12-year follow-up of surgery versus surveillance in the
UK Small Aneurysm Trial. Br J Surg 2007;94:702-8.
5. Schermerhorn ML, O’Malley AJ, Jhaveri A, Cotterill P, Pomposelli F,
Landon BE. Endovascular vs. open repair of abdominal aortic aneu-
rysms in the Medicare population. N Engl J Med 2008;358:464-74.
6. Blankensteijn JD, de Jong SE, Prinssen M, an der Ham AC, Buth J, van
Sterkenburg SM, et al. Two-year outcomes after conventional or endo-
vascular repair of abdominal aortic aneurysms. N Engl JMed 2005;352:
2398-405.
7. Greenhalgh RM, Brown LC, Kwong GP, Powell JT, Thompson SG.
Comparison of endovascular aneurysm repair with open repair in pa-
tients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative
mortality results: randomised controlled trial. Lancet 2004;364:843-8.
8. United Kingdom Small Aneurysm Trial Participants. Long-term out-
comes of immediate repair compared with surveillance of small abdom-
inal aortic aneurysms. N Engl J Med 2002;346:1445-52.
9. Ouriel K, Srivastava SD, Sarac TP, O’hara PJ, Lyden SP, Greenberg RK,
et al. Disparate outcome after endovascular treatment of small versus
large abdominal aortic aneurysm. J Vasc Surg 2003;37:1206-12.
10. Bengtsson H, Bergqvist D. Ruptured abdominal aortic aneurysm: a
population-based study. J Vasc Surg 1993;18:74-80.
11. MLNMatters. MM 5235, 1-4. Dec 8, 2006. Centers for Medicare and
Medicaid Services. Feb 17, 2008.
12. Schermerhorn ML, Cronenwett JL. The UK small aneurysm trial. J
Vasc Surg 2001;33:443.
13. Schlösser FJ, Tangelder MJ, Verhagen HJ, van der Heijden GJ, Muhs
BE, van der Graaf Y, et al. Growth predictors and prognosis of small
abdominal aortic aneurysms. J Vasc Surg 2008;47:1127-33.
14. Baxter BT, Terrin MC, Dalman RL. Medical management of small
abdominal aortic aneurysms. Circulation 2008;117:1883-9.Submitted Aug 8, 2009; accepted Oct 22, 2009.
